Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rexer

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Der Urologe. Ausg. A|March 2, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO]H Rexer, J Bedke
Der Urologe. Ausg. A|October 26, 2016
[PROKOMB - prostate-cooperative MRI project Berlin-study AP 95/16 of the AUO]H Rexer, M Graefen
Der Urologe. Ausg. A|July 2, 2017
[Adjuvant radiotherapy for lymph-node-positive prostate cancer with low tumor load after radical prostatectomy : Multicenter randomized phase III study of the effect of adjuvant radiotherapy in patients with prostate cancer with or without a positive margin after radical prostatectomy (RP) and lymph node metastasis with low tumor load (micrometastases, ≤ 2 lymph node macrometastases). ART-2 - study AP 61/10 of the AUO]H Rexer, D Bartkowiak
Aktuelle Urologie|November 8, 2017
H Rexer, P Hammerer
Der Urologe. Ausg. A|December 16, 2015
[Non-interventional study for the treatment of neutropenia: Use of pegfilgrastim for chemotherapy-induced neutropenia]C Wülfing, H Rexer
Der Urologe. Ausg. A|June 17, 2016
[First-line treatment of unresectable, stage IV transitional cell carcinoma]H Rexer, C Ohlmann
Der Urologe. Ausg. A|June 24, 2011
[3rd European Consensus Meeting for testicular cancer]H Rexer, S Krege
Aktuelle Urologie|April 6, 2021
H Rexer, P Hammerer
Der Urologe. Ausg. A|January 29, 2016
[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14]H Rexer, P Hammerer
Der Urologe. Ausg. A|September 18, 2016
[Neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer]H Rexer, A Merseburger
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Der Urologe. Ausg. A|March 2, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO]H Rexer, J Bedke
Der Urologe. Ausg. A|October 26, 2016
[PROKOMB - prostate-cooperative MRI project Berlin-study AP 95/16 of the AUO]H Rexer, M Graefen
Der Urologe. Ausg. A|July 2, 2017
[Adjuvant radiotherapy for lymph-node-positive prostate cancer with low tumor load after radical prostatectomy : Multicenter randomized phase III study of the effect of adjuvant radiotherapy in patients with prostate cancer with or without a positive margin after radical prostatectomy (RP) and lymph node metastasis with low tumor load (micrometastases, ≤ 2 lymph node macrometastases). ART-2 - study AP 61/10 of the AUO]H Rexer, D Bartkowiak
Aktuelle Urologie|November 8, 2017
H Rexer, P Hammerer
Der Urologe. Ausg. A|December 16, 2015
[Non-interventional study for the treatment of neutropenia: Use of pegfilgrastim for chemotherapy-induced neutropenia]C Wülfing, H Rexer
Der Urologe. Ausg. A|June 17, 2016
[First-line treatment of unresectable, stage IV transitional cell carcinoma]H Rexer, C Ohlmann
Der Urologe. Ausg. A|June 24, 2011
[3rd European Consensus Meeting for testicular cancer]H Rexer, S Krege
Aktuelle Urologie|April 6, 2021
H Rexer, P Hammerer
Der Urologe. Ausg. A|January 29, 2016
[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14]H Rexer, P Hammerer
Der Urologe. Ausg. A|September 18, 2016
[Neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer]H Rexer, A Merseburger
Pageof 11